GlassScriptPhysician profile
H T Levine
NPI 1366548893
$2,550.51
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $852 · 2020: $85.02 · 2021: $796 · 2022: $727 · 2023: $90.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $64.86 · Consulting Fee: $25.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $64.86 |
| Consulting Fee | $25.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $509.99 | 2019-2022 | |
| Genentech USA, INC. | $388.81 | 2019-2023 | Xolair |
| Glaxosmithkline, LLC. | $325.62 | 2019-2022 | |
| Abbvie INC. | $170.97 | 2021-2022 | |
| Genzyme Corporation | $132.05 | 2021 | |
| Blueprint Medicines Corporation | $131.22 | 2022 | |
| Pfizer INC. | $127.49 | 2019-2022 | |
| Leo Pharma INC. | $123.73 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $104.85 | 2019-2021 | |
| Adma Biomanufacturing LLC | $104.15 | 2022-2023 | |
| Sunovion Pharmaceuticals INC. | $62.70 | 2019 | |
| Grifols USA, LLC | $62.60 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $52.30 | 2019-2021 | |
| Csl Behring | $43.80 | 2023 | Haegarda, Kcentra |
| Biocryst US Sales Co., LLC | $37.27 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $34.08 | 2019 | |
| Pharming Healthcare, INC. | $24.53 | 2019 | |
| Amgen INC. | $23.13 | 2021 | |
| Allergan, INC. | $21.54 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.95 | 2022 | |
| Kaleo, INC. | $13.07 | 2019 | |
| Aimmune Therapeutics, INC. | $12.90 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.12 | 2019 | |
| Merck Sharp & Dohme LLC | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw H Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.